Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieSalah‐Eddin Al‐Batran, Elke Jäger, J. T. Hartmann et al.|Journal of Clinical Oncology|2008Cited by 784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Ralf‐Dieter Hofheinz et al.|The Lancet Oncology|2016Cited by 738
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerSalah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Nils Homann et al.|JAMA Oncology|2017Cited by 473
NY‐ESO‐1: Review of an Immunogenic Tumor AntigenSacha Gnjatic, Lloyd J. Old, Hiroyoshi Nishikawa et al.|Advances in cancer research|2006Cited by 455
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersElke Jäger, Alexander Knuth, Sacha Gnjatic et al.|Proceedings of the National Academy of Sciences|2000Cited by 426